Literature DB >> 10210887

The burden of migraine to the individual sufferer: a review.

.   

Abstract

This review of the literature reveals that migraine is a common, chronic condition featuring episodic attacks which vary in severity and symptomatology. Throbbing, unilateral headache, which is aggravated by activity, is the most prominent feature, although a high proportion of sufferers also experience phonophobia, photophobia and nausea, which may lead to vomiting. Preceding aura is a less common feature of the attack. The frequency and duration of migraine attacks varies widely between individuals, though the median frequency is around 1 attack per month and median duration is roughly 24 h. Migraine attacks can have a profound effect on the day-to-day lives and well-being of the sufferer. In the long term, migraine may cause profound emotional changes and result in coping strategies that interfere with working, social and family life and many normal daily activities. These effects are apparent in quality of life studies on migraine patients. Thus, the impact of migraine on many quality of life parameters is similar to that of other chronic conditions such as osteoarthritis, diabetes and depression. Reduction in the personal burden of migraine can be facilitated by encouraging migraine sufferers to consult their doctor, through accurate diagnosis of migraine headaches and assessment of the disability suffered by the migraineurs, and through improved and well-executed treatment strategies. Copyright 1998 Lippincott Williams & Wilkins

Entities:  

Year:  1998        PMID: 10210887     DOI: 10.1046/j.1468-1331.1998.560525.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  13 in total

1.  Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine.

Authors:  David W Dodick; Giorgio Sandrini; Paul Williams
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

2.  Adverse reactions related to drugs for headache treatment: clinical impact.

Authors:  Anna Ferrari; Alessandra Ottani; Alfio Bertolini; Arrigo Francesco Giuseppe Cicero; Ciro Pio Rosario Coccia; Sheila Leone; Emilio Sternieri
Journal:  Eur J Clin Pharmacol       Date:  2005-01-19       Impact factor: 2.953

3.  The cost effectiveness of stratified care in the management of migraine.

Authors:  P Williams; A J Dowson; A M Rapoport; J Sawyer
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 4.  Delivery systems for acute migraine medications.

Authors:  I Worthington
Journal:  Can Fam Physician       Date:  2001-02       Impact factor: 3.275

5.  Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial.

Authors:  Catherine Buettner; Rony-Reuven Nir; Suzanne M Bertisch; Carolyn Bernstein; Aaron Schain; Murray A Mittleman; Rami Burstein
Journal:  Ann Neurol       Date:  2015-11-13       Impact factor: 10.422

6.  Health care utilization and changes in health status over time for migraineurs.

Authors:  Anderson Chuck; Philip Jacobs; Arto Ohinmaa; Donald Schopflocher; Saifudin Rashiq; Racquel Feroe
Journal:  Pain Res Manag       Date:  2007       Impact factor: 3.037

7.  Need for care and perceptions of MIDAS among headache sufferers study.

Authors:  Walter Stewart; Richard Lipton
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 8.  Newer formulations of the triptans: advances in migraine management.

Authors:  Jonathan Paul Gladstone; Marek Gawel
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Comparison of validity and reliability of the Migraine disability assessment (MIDAS) versus headache impact test (HIT) in an Iranian population.

Authors:  Abbas Ghorbani; Ahmad Chitsaz
Journal:  Iran J Neurol       Date:  2011

10.  Quality of life and migraine disability among female migraine patients in a tertiary hospital in Malaysia.

Authors:  Munvar Miya Shaik; Norul Badriah Hassan; Huay Lin Tan; Siew Hua Gan
Journal:  Biomed Res Int       Date:  2015-01-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.